BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

  Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update, and reported financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  10 min read
• Business

  Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

  Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the quarter ended March 31, 2024.

  May 9, 2024

   · 

  10 min read
• Business

  Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

  Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  8 min read
• Genetown

  Morphic to Participate in RBC Capital Markets Global Healthcare Conference

  Morphic Therapeutic announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.

  May 9, 2024

   · 

  1 min read
• Business

  Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

  Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

  May 9, 2024

   · 

  12 min read
• Business

  ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

  ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

  May 9, 2024

   · 

  11 min read
• Business

  Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

  Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, reported financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  8 min read
• Business

  IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

  IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

  May 9, 2024

   · 

  9 min read
• Business

  Acutus Medical Reports First Quarter 2024 Financial Results

  Acutus Medical, Inc. reported results for the first quarter of 2024.

  May 9, 2024

   · 

  8 min read
• Business

  INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

  INmune Bio Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its financial results for the quarter ended March 31, 2024 and provides a business update.

  May 9, 2024

   · 

  13 min read